28. Beovu

Beovu drug box

Active ingredient: brolucizumab
Disease: wet age-related macular degeneration
Peak sales estimate: $1 billion
Approved: Oct. 8, 2019
Company: Novartis

The scoop: Novartis' Beovu scored an approval in October to challenge Regeneron and Roche blockbusters in wet age-related macular degeneration. The FDA backed Beovu based on two studies that pitted it against Eylea and showed that the new medication could match Eylea on efficacy. The drug topped Eylea on secondary endpoints that looked at retinal fluid and central subfield thickness. Analysts had some concern about the drug’s label following approval, but a Novartis executive told FiercePharma the company is happy with its label. With both of the entrenched medications in the field—Eylea and Lucentis—facing 2020 patent expirations, biosimilars could eat away at pricing as Novartis seeks to grow sales for its new offering. Still, analysts expect the drug to generate more than $1 billion and top the market by 2026. — Eric Sagonowsky

28. Beovu

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.